Latest news with #ECCO
Daily Mail
27-05-2025
- Business
- Daily Mail
Katie Holmes just wore this exact pair of affordable white trainers - and they're still in stock
is no stranger to a viral streetwear moment. There was the time she was snapped hailing a taxi in a sexy-cosy bra and cardigan set from premium label Khaite, and the internet went into such a frenzy, the £2,065 combo sold out within the hour. Then there's her beloved Dune XL Woven Tote – her go-to for pairing with a slouchy jumper – which has been restocked four times as shoppers scramble to copy her look. The actress puts it down to shopping for 'accessible and classic' items. In an interview with Vogue, Holmes said her main requirement when shopping is the longevity of a piece and her ability to wear it season after season. We love a level-headed and sustainable celebrity who knows the importance of investing in high-quality staples, even if they are sometimes a smidge out of our price range. What it does mean, however, is that when Katie Holmes does wear something affordable, you know the quality and design hold up to the high standards she expects of her designer go-to items. So when the 46-year-old recently stepped out in the perfect pair of £140 white trainers, you best believe we immediately clicked 'add to basket'. The shoes in question are Danish brand ECCO's BIOM 2.2 Sneakers, and it's clear to see why Holmes is such a fan. They perfectly embody the athleisure trend without being too chunky (let's be honest, some of the massive sporty styles make your legs look ridiculous), and as such are ideal whether you're going to the gym, dressing down an office suit or giving a summer nap dress a 2025 twist. Another win? The trainers feel as good as they look. ECCO is renowned for its LYTR tech, which encourages a natural gait while gripping and supporting your foot – so no more blisters when you're running up the escalator on your commute (or taking an impromptu walk to the pub). The shoes are also made with leather and suede from ECCO's own tanneries, so you're guaranteed a high-quality sneaker that really lasts. Holmes' exact ECCO BIOM 2.2 Sneakers in white suede are available now at We're shopping before they sell out, and highly recommend you do the same.
Daily Mail
26-05-2025
- Lifestyle
- Daily Mail
'These are so comfortable': The sandals every jet-setter and hiker is wearing this summer - and they say they're the best they've ever owned
A pair of lightweight sandals are being hailed the most comfortable shoe of the summer - and they're a winner among hikers and travellers. Shoppers looking for sandals to help them rack up 10,000 steps a day this summer are being recommended the ECCO Offroad sandals time and time again. Functional yet fashionable, the supportive sandal has been designed to carry you through various terrain - whether that's exploring European cobbles streets or mountains. The £100 lightweight hiking sandals that travellers love could be your ticket to blister-free walks this summer. Tested over hundreds of miles and across various terrain by jet-setting shoppers, the ECCO Offroad sandals have come up trumps by those looking for comfortable sandals that are up to a challenge. Lightweight and supportive, the Offroad sandal range promises superior comfort, whether that's everyday walking or comfort on longer trails. And with a choice of 12 colours, it's no wonder why shoppers are coming back for more. Finding a pair of sandals that won't rub throughout the day is no easy feat, particularly when you don't have time to rush back and change your footwear. But Danish brand ECCO seems to have cracked it, and it has racked up a loyal list of fans. Sleek Danish design combined with comfort orientated features and benefits has meant the ECCO Offroad sandals are continuously being toted as some of the most comfortable sandals out there. 'Extremely comfortable, stylish, hard wearing,' raved one shopper. 'Wouldn't be without a pair of these sandals.' This is all thanks to its function forward design. Far from your bog-standard, often thin-soled sandal, these have been created with a moulded EVA footbed for supreme cushioning and superior stability so can deal with hillside walks and city streets alike. 'These are so comfortable,' agreed another. 'I find them my first choice to wear, even if not on an 'walk'. I wore them for the first time on an 12 km walk, with no problem. The soles are thick enough to protect against uneven paths, and I like the look.' This 'look' is part of the 'gorpcore' trend, which embraces the technical elements of a hiking, climbing aesthetic but with a fashion twist. The ECCO Offroad has a chunky design with grippy sole that embodies the revival of 'dad' and 'gorpcore' sandals and has gone on to be widely celebrated for their retro, pragmatic appeal. If you want to navigate summer with a high step count, then scores have given these their seal of approval. 'Perfect for long walks and travel, they are comfortable from the first time,' added one shopper. 'A durable supporting sole and good range of strap adjustment. I like the colour range and may consider a second pair'.
Cision Canada
09-05-2025
- Health
- Cision Canada
Strengthening Community Care for Ontarians: A Call for Action from Nurses
TORONTO, /CNW/ - To mark the start of National Nursing Week (May 12-18, 2025), the Registered Nurses' Association of Ontario (RNAO) will release highly anticipated evidence-based recommendations to transform the health system for the benefit of all Ontarians. RNAO will unveil its new report – ECCO 4.0: Enhancing Community Care for Ontarians – during a media conference at Queen's Park. ECCO 4.0 builds on three previous reports released in 2012, 2014 and 2020, all centred on strengthening community care. Each edition of ECCO advances a vision for a health system anchored in primary care – one that is accessible, equitable, person-centred, integrated and publicly funded on a not-for-profit basis. While the core ECCO model remains unchanged, each report addresses real-time system planning challenges and emerging needs. "Ontario is at last positioning primary care and community care as important to health system transformation" says RNAO President NP Lhamo Dolkar, adding that "to accelerate progress government must double down on the functions and funding of primary care, home care, and other community care services." " ECCO 4.0 critically evaluates developments over the past five years and presents targeted recommendations for the government and health system partners," Dolkar adds. "By anchoring the system in primary care and enhancing community services, we can achieve a more responsive, cost-effective and resilient health system." "This report is an urgent call for action given the intersecting challenges affecting our province. These include primary care access, toxic drugs, access to affordable housing, food insecurity, the climate crisis, and a relentless health human resource shortage including registered nurses and nurse practitioners," says RNAO CEO Dr. Doris Grinspun. " ECCO 4.0 offers a clear and actionable blueprint on how to immediately address current challenges and build a high-performing health system rooted in equity, diversity and inclusion. It is designed to improve access, care quality and outcomes for everyone in Ontario. We are eager to share this report with elected leaders, health system partners and the public – so we can work together to deliver health for all." WHAT: RNAO releases ECCO 4.0: Enhancing Community Care for Ontarians to kickoff National Nursing Week. Moderator: Immediate Past-President Dr. Claudette Holloway President NP Lhamo Dolkar CEO Dr. Doris Grinspun WHEN: Monday, May 12 at 10 a.m. ET at Queen's Park media studio Members of the media are welcome to attend. The Registered Nurses' Association of Ontario (RNAO) is the professional association representing registered nurses, nurse practitioners and nursing students in Ontario. Since 1925, RNAO has advocated for healthy public policy, promoted excellence in nursing practice, increased nurses' contribution to shaping the health system, and influenced decisions that affect nurses and the public we serve. For more information about RNAO, visit or follow us on X (formerly Twitter), Facebook, Instagram and LinkedIn. SOURCE Registered Nurses' Association of Ontario
Vogue Singapore
22-04-2025
- Entertainment
- Vogue Singapore
Yuna fronts ECCO's Icons That Last campaign in Southeast Asia Vogue Singapore
ECCO, known for comfort and rooted in quality craftsmanship, steps forward once again. This time, the Danish brand introduces a day-to-night heel that melds comfort with quiet glamour. For women, the day doesn't always end when the clock says so—it stretches, twists, and packs everything into those same 24 hours: back-to-back meetings, last-minute dinner plans, even the occasional squeeze of a late-night workout session. Presentation still matters, but comfort can't be an afterthought. And while the old saying goes 'beauty is pain', today's fashion tech is challenging that, with this new silhouette as proof. Malaysian singer-songwriter Yuna is the face of ECCO's Icons That Last campaign in Southeast Asia. Courtesy of ECCO Yuna is the new face of ECCO's Icons That Last campaign in Southeast Asia—a perfectly fitting choice. The Malaysian singer-songwriter is no stranger to packed schedules, flitting from stage to studio to front row. And it's no surprise the 38-year-old is fronting the campaign, with her chic modest style and bold performance looks making her a sartorial inspiration for many. And this silhouette? It's the perfect companion for a modish powerhouse like Yuna. Made with ergonomic midsoles, pressure-absorbing padding, and a range of heel heights, this collection blends comfort with charm. Courtesy of ECCO With the sophistication of a heel and the confidence it brings, this piece doesn't ask its wearer to trade function for flair. Thanks to ECCO's longstanding expertise and innovations like the signature Fluidform™ Direct PU Injection technology, ergonomic midsoles, and pressure-absorbing padding, this is a heel made for movement. The result? A shoe that lets you flow from place to place—no extra comfort sneakers in your tote, no compromises made. Crafted in a range of styles and shades, there is a design for every occasion. Courtesy of ECCO Available in a variety of styles and heel heights, it caters to every kind of day. There are front-strap options for added support, more relaxed heel heights for off-duty ease, and of course, the always-reliable classic black. A standout this season is the Alba Sling sandals—a versatile silhouette that complements every ensemble, a simple yet bold way to stay stylish without skimping on comfort. A highlight of this collection is the Alba Sling sandals, a bold silhouette that effortlessly elevates any look. Courtesy of ECCO Ultimately, it's a heel designed for real life—one that understands the rhythm of a full day and the need to look polished without forgoing ease. With ECCO's new collection, comfort no longer needs to be a sacrifice, it's part of the statement. For more information and to shop the collection, visit ECCO.
Yahoo
09-04-2025
- Health
- Yahoo
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the Company will present further efficacy and safety data1 from the 24-week Open Label Extension (OLE) period from CoTikiS Phase 2 clinical study of Lusvertikimab in ulcerative colitis at the Digestive Disease Week conference in San Diego (May 3 – 6, 2025). Following the excellent efficacy and safety profile from the trial's induction period presented as a highlight at the 2025 ECCO congress, this oral presentation will unveil new clinical data from the 24-week Open Label Extension (OLE) period (Week 10 to Week 34) of the randomized, double-blind, placebo-controlled Phase 2 study evaluating the anti-IL-7 receptor monoclonal antibody Lusvertikimab in moderate to severe ulcerative colitis. These new findings are expected to provide deeper insights into the long-term benefits and safety of Lusvertikimab, supporting further development in ulcerative colitis, as well as in other chronic autoimmune and inflammatory diseases. Presentation details: Title: 'LUSVERTIKIMAB, A FIRST IN CLASS IL7 RECEPTOR ANTAGONIST, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A MULTICCENTER RANDOMIZED PLACEBO-CONTROLLED PHASE II STUDY' Date and Time: Monday, May 05, 2025, from 4:45pm to 5:00pm Pacific TimeSession Presentation: Clinical Trials in IBD: Biologics and Emerging TherapiesSession Number: 0004 ABOUT ULCERATIVE COLITIS (UC)Ulcerative colitis is a chronic disease of the large intestine, or colon, and rectum, in which the lining of the gastrointestinal tract becomes inflamed and develops ulcers. This condition is the result of an overactive immune system. UC affects 3.3 million patients in the US, Europe and Japan2. Despite broad therapeutic options, remission rates are only 25-30%3 leaving most patients without satisfactory treatments. 15% of patients4 fail to respond to all therapies and undergo surgery as a last option. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 The abstract was submitted before the completion of the 24-week Open Label Extension (OLE) period. The new data to be presented at DDW 2025 includes additional findings not available at the time of submission.2 Evaluate Pharma3 Drugs Context. 2019; 8: 212572 –doi: 10.7573/dic.2125724 Scientific Reports volume 10, Article number: 12546 (2020) Attachment EN_250409_DDW_Lusvertikimab_vfSign in to access your portfolio
